Superficial Necrolytic Dermatitis in 11 Dogs with a History of Phenobarbital Administration (1995-2002)

Journal of Veterinary Internal Medicine

Volumn 18, Issue 1, 2004, Pages 65-74

  March, Philip A ^a   Hillier, Andrew ^a   Weisbrode, Steven E ^a   Mattoon, John S ^a   Johnson, Susan E ^a   DiBartola, Stephen P ^a   Brofman, Peter J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Amino acids; Canine; Cirrhosis; Hepatocutaneous syndrome; Hepatopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINO ACID; PHENOBARBITAL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMATITIS; DOG DISEASE; ECHOGRAPHY; HISTOPATHOLOGY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TOXICITY; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; RADIOGRAPHY; RETROSPECTIVE STUDY; SKIN DISEASE; SKIN TOXICITY; SUPERFICIAL NECROLYTIC DERMATITIS;

ALANINE TRANSAMINASE; ANIMALS; ANTICONVULSANTS; DOG DISEASES; DOGS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HEPATITIS, TOXIC; ILLINOIS; MALE; OHIO; PEDIGREE; PHENOBARBITAL; RECORDS; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

ANIMALIA; CANIS FAMILIARIS;

EID: 0842265694     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2004)18<65:SNDIDW>2.0.CO;2     Document Type: Article

References (74)

1. Gross TL, Song MD, Havel PJ, et al. Superficial necrolytic dermatitis (necrolytic migratory erythema) in dogs. Vet Pathol 1993;30: 75-81.
2. Jacobson LS, Kirberger RM, Nesbit JW. Hepatic ultrasonography and pathological findings in dogs with hepatocutaneous syndrome: New concepts. J Vet Intern Med 1995;9:399-404.
3. McNeil PE. The underlying pathology of the hepatocutaneous syndrome: A report of 18 cases. In: Ihrke PJ, Mason IS, White SD, eds. Advances in Veterinary Dermatology. Oxford, UK, and New York, NY: Pergamon Press; 1992:113-129.
4. Bond R, McNeil PE, Evans H, et al. Metabolic epidermal necrosis in two dogs with different underlying diseases. Vet Rec 1995;136: 466-471.
5. Byrne KP. Metabolic epidermal necrosis-hepatocutaneous syndrome. Vet Clin North Am Small Anim Pract 1999;29:1337-1355.
6. Miller WH, Scott DW, Buerger RG, et al. Necrolytic migratory erythema in dogs: A hepatocutaneous syndrome. J Am Anim Hosp Assoc 1990;26:573-581.
7. Turnwald GH, Foil CS, Wolfsheimer KJ, et al. Failure to document hyperglucagonemia in a dog with diabetic dermatopathy resembling necrolytic migratory erythema. J Am Anim Hosp Assoc 1989; 25:363-369.
8. Florant E, Guillot J, Degorce-Rubiales F, et al. Four cases of canine metabolic epidermal necrosis. Vet Dermatol 2000;11:18.
9. Haitjema H. Metabolic epidermal necrosis associated with hepatopathy in a dog. Aust Vet Pract 1995;25:20-25.
10. Taboada J, Merchant SR. Superficial necrolytic dermatitis and the liver. American College of Veterinary Internal Medicine 15th Annual Veterinary Medical Forum, Lake Buena Vista, FL, 1997:534-537.
11. Outerbridge CA, Marks SL, Rogers QR. Plasma amino acid concentrations in 36 dogs with histologically confirmed superficial necrolytic dermatitis. Vet Dermatol 2002;13:177-186.
12. Nyland TG, Barthez PY, Ortega TM, et al. Hepatic ultrasonographic and pathologic findings in dogs with canine superficial necrolytic dermatitis. Vet Radiol Ultrasound 1996;37:200-205.
13. Walton DK, Center SA, Scott DW, et al. Ulcerative dermatosis associated with diabetes mellitus in the dog: A report of four cases. J Am Anim Hosp Assoc 1986;22:79-88.
14. Torres SM, Caywood DD, O'Brien TD, et al. Resolution of superficial necrolytic dermatitis following excision of a glucagon-secreting pancreatic neoplasm in a dog. J Am Anim Hosp Assoc 1997; 33:313-319.
15. Torres S, Johnson K, McKeever P, et al. Superficial necrolytic dermatitis and a pancreatic endocrine tumour in a dog. J Small Anim Pract 1997;38:246-250.
16. Gross TL, O'Brien TD, Davies AP, et al. Glucagon-producing pancreatic endocrine tumors in two dogs with superficial necrolytic dermatitis. J Am Vet Med Assoc 1990;197:1619-1622.
17. Miller WH, Anderson WI, McCann JP. Necrolytic migratory erythema in a dog with a glucagon-secreting endocrine tumor. Vet Dermatol 1991;2:179-182.
18. Langer N, Jergens AE, Miles KG. Canine glucagonoma. Compend Contin Educ Pract Vet 2003;25:56-63.
19. Allenspach K, Arnold P, Glaus T, et al. Glucagon-producing pancreatic endocrine tumors in dogs with superficial necrolytic dermatitis. J Small Anim Pract 2000;41:402-406.
20. Chastain MA. The glucagonoma syndrome: A review of its features and discussion of new perspectives. Am J Med Sci 2001;321: 306-320.
21. Little C, McNeil PE, Robb J. Hepatopathy and dermatitis in a dog associated with the ingestion of mycotoxins. J Small Anim Pract 1991;32:23-26.
22. Foster AP, Panciera DL, Cooley AJ. Recognizing canine hepatocutaneous syndrome. Vet Med 1997;92:1050-1055.
23. Bloom P, Rosser E, Dunstan R. Anti-convulsant hepatitis-induced necrolytic migratory erythema. Proceedings of the Second World Congress of Veterinary Dermatology, Montreal, Quebec, 1992: 56.
24. Henricks PM. Dermatitis associated with the use of primidone in a dog. J Am Vet Med Assoc 1987;191:237-238.
25. Dayrell-Hart B, Steinberg SA, VanWinkle TJ, et al. Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989). J Am Vet Med Assoc 1991;199:1060-1066.
26. Bunch SE, Castleman WL, Hornbuckle WE, et al. Hepatic cirrhosis associated with long-term anticonvulsant drug therapy in dogs. J Am Vet Med Assoc 1982;181:357-362.
27. Center SA. Pathophysiology and laboratory diagnosis of hepatobiliary disorders. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat, 4th ed. Philadelphia, PA: WB Saunders; 1995:1261-1312.
28. Center SA. Diagnostic procedures for evaluation of hepatic disease. In: Guilford WG, Center SA, Strombeck DR, et al, eds. Strombeck's Small Animal Gastroenterology, 3rd ed. Philadelphia, PA: WB Saunders; 1996:130-188.
29. Johnson SE. Diseases of the liver. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat, 4th ed. Philadelphia, PA: WB Saunders; 1995:1313-1357.
30. Rutgers HC, Hayward S. Chronic hepatitis in the dog. J Small Anim Pract 1988;29:679-690.
31. Hardy R. Diseases of the liver and their treatment. In: Ettinger SJ, ed. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat, 3rd ed. Philadelphia, PA: WB Saunders; 1989:1479-1527.
32. Strombeck D, Gribble DG. Chronic active hepatitis in the dog. J Am Vet Med Assoc 1978;173:380-386.
33. Strombeck DR, Rogers Q. Plasma amino acid concentrations in dogs with hepatic disease. J Am Vet Med Assoc 1978;173:93-96.
34. Strombeck DR, Harrold D, Rogers Q, et al. Plasma amino acid, glucagon, and insulin concentrations in dogs with nitrosamine-induced hepatic disease. Am J Vet Res 1983;44:2028-2036.
35. Cooper AJL. Amino acid metabolism and synthesis of urea. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease, 4th ed. Philadelphia, PA: WB Saunders; 2003:81-126.
36. Saxena R, Zucker SD, Crawford JM. Anatomy and physiology of the liver. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease, 4th ed. Philadelphia, PA: Saunders; 2003:3-30.
37. Gumucio J, Chiamale J. Liver cell heterogeneity and liver function. In: Arias IM, Jacoby WB, Popper H, et al, eds. The Liver: Biology and Pathobiology, 2nd ed. New York, NY: Raven Press; 1988: 931-948.
38. Tews JK, Woodcock NA, Harper AE. Stimulation of amino acid transport in rat liver slices by epinephrine, glucagon, and adenosine 3′,5′- monophosphate. J Biol Chem 1970;245:3026-3032.
39. Chu CA, Sindelar DK, Igawa K, et al. The direct effects of catecholamines on hepatic glucose production occur via alpha(1)-and beta(2)-receptors in the dog. Am J Physiol Endocrinol Metab 2000; 279:E463-E473.
40. Roth E, Muhlbacher F, Karner J, et al. Free amino acid levels in muscle and liver of a patient with glucagonoma syndrome. Metab Clin Exp 1987;36:7-13.
41. Van Thiel D. The liver and endocrine system. In: Arias IM, Jacoby WB, Popper H, et al, eds. The Liver: Biology and Pathobiology, 2nd ed. New York, NY: Raven Press; 1988:1007-1032.
42. Poli G, Cassader M, Chiarpotto E, et al. Age related changes of glucagon binding and activity in isolated rat hepatocytes. Int J Tissue React 1986;8:367-371.
43. Leoni S, Spagnuolo S, Massimi M, et al. Epinephrine regulation of amino acid transport in rat hepatocytes isolated during development. Memb Biochem 1990;9:117-128.
44. Kilberg MS, Handlogten ME, Christensen HN. Characteristics of an amino acid transport system in rat liver for glutamine, asparagine, histidine, and closely related analogs. J Biol Chem 1980;255: 4011-4019.
45. Bracy DS, Handlogten ME, Barber EF, et al. Cis-inhibition, trans-inhibition, and repression of hepatic amino acid transport mediated by System A. Substrate specificity and other properties. J Biol Chem 1986;261:1514-1520.
46. Chambers JW, Georg RH, Bass AD. Effects of catecholamines and glucagon on amino acid transport in the liver. Endocrinology 1968; 83:1185-1192.
47. Dax EM, Partilla JS, Pineyro MA, et al. Beta-adrenergic receptors, glucagon receptors, and their relationship to adenylate cyclase in rat liver during aging. Endocrinology 1987;120:1534-1541.
48. Kalish MI, Katz MS, Pineyro MA, et al. Epinephrine-and glucagon-sensitive adenylate cyclases of rat liver during aging. Evidence for membrane instability associated with increased enzymatic activity. Biochim Biophys Acta 1977;483:452-466.
49. Leoni S, Spagnuolo S, Dini L, et al. Regulation of amino acid transport in hepatocytes isolated from adult and old rats. Mech Ageing Dev 1988;46:19-27.
50. Houslay MD. Coupling of the glucagon receptor to adenylate cyclase. Biochem Soc Trans 1979;7:843-846.
51. Simonson DC, DeFronzo RA. Glucagon physiology and aging: Evidence for enhanced hepatic sensitivity. Diabetologia 1983;25:1-7.
52. Litterst CL, Farber TM, Van Loon EJ. Potentiation of CC14-induced hepatotoxicity in the dog by chronic exposure to phenobarbital. Toxicol Appl Pharmacol 1973;25:354-362.
53. Trepanier L. Hepatic drug metabolism in the dog and cat: What's relevant for the internist? American College of Veterinary Internal Medicine 20th Annual Veterinary Medical Forum, Dallas, TX, May, 2002:666-668.
54. DePierre JW, Andersson G, Dallner G. Endoplasmic reticulum and Golgi complex. In: Arias IM, Jacoby WB, Popper H, et al, eds. The Liver: Biology and Pathobiology, 2nd ed. New York, NY: Raven Press; 1988:165-188.
55. Vessey D. Hepatic metabolism of xenobiotics in humans. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease, 4th ed. Philadelphia, PA: WB Saunders; 2003:185-232.
56. Hojo T, Ohno R, Shimoda M, et al. Enzyme and plasma protein induction by multiple oral administrations of phenobarbital at a therapeutic dosage regimen in dogs. J Vet Pharmacol Ther 2002;25:121-127.
57. Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992;281:577-592.
58. Cacciatore L, Budillon G, De Marco F, et al. Pattern and concentration of free amino acids in the plasma and liver tissue of phenobarbital-treated rats. Res Commun Chem Pathol Pharmacol 1978; 19:537-540.
59. Blankenship J, Kuehl L. Effects of phenobarbital and 3- methylcholanthrene on amino acid incorporation into rat liver chromosomal proteins. Mol Pharmacol 1973;9:247-258.
60. Garner RC, McLean AE. The effect of phenobarbitone on the incorporation of delta-aminolaevulinic acid into rat liver microsomes. Biochem J 1969;114:7P.
61. Jondorf WR, Simon DC, Avnimelech M. The stimulation of amino acid incorporation in a mammalian system with phenobarbital, 3-methylcholanthrene and cycloheximide. Biochem Biophys Res Commun 1966;22:644-649.
62. Argaud D, Halimi S, Catelloni F, et al. Inhibition of gluconeogenesis in isolated rat hepatocytes after chronic treatment with phenobarbital. Biochem J 1991;280:663-669.
63. Cajone F, Bernelli-Zazzera A. The effect of phenobarbital on protein metabolism of liver: Results with isolated hepatocytes. Biochem Pharmacol 1984;33:725-729.
64. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 1994;331:847-853.
65. Motomura K, Brent GA. Mechanisms of thyroid hormone action. Implications for the clinical manifestation of thyrotoxicosis. Endocrinol Metab Clin North Am 1998;27:1-23.
66. Hellerstein M, Munro HN. Interaction of liver and muscle in the regulation of metabolism in response to nutritional and other factors. In: Arias IM, Jacoby WB, Popper H, et al, ed. The Liver: Biology and Pathobiology, 2nd ed. New York, NY: Raven Press; 1988:965-984.
67. Smith RJ. Glutamine metabolism and its physiologic importance. J Parenter Enteral Nutr 1990;14:40S-44S.
68. Haake AR, Holbrook K. The structure and development of skin. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine, 5th ed. New York, NY: McGraw-Hill; 1999:70-114.
69. Latkowski JM, Freedberg IM. Epidermal cell kinetics, epidermal differentiation, and keratinization. In: Freedberg IM, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine, 5th ed. New York, NY: McGraw-Hill; 1999:133-143.
70. Papaconstantinou HT, Hwang KO, Rajaraman S, et al. Glutamine deprivation induces apoptosis in intestinal epithelial cells. Surgery 1998;124:152-159; discussion 159-160.
71. Behar KL, Rothman DL. In vivo nuclear magnetic resonance studies of glutamate-gamma-aminobutyric acid-glutamine cycling in rodent and human cortex: The central role of glutamine. J Nutr 2001; 131:2498S-2504S; discussion 2523S-2524S.
72. Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 2000;130:1016S-1022S.
73. Edwards DJ, Virji MA. Hypoaminoacidemia caused by imipramine but not by clenbuterol is dissociable from hyperglycemia and hyperinsulinemia. Life Sci 1990;47:L13-L18.
74. Haussinger D, Graf D, Weiergraber OH. Glutamine and cell signaling in liver. J Nutr 2001;131:2509S-2514S; discussion 2523S-2524S.